[Ip-health] UK moving closer to ‘Crown use’ (compulsory licence) to access generic cystic fibrosis drug

Ellen 't Hoen ellenthoen at medicineslawandpolicy.net
Mon Jun 10 21:08:12 PDT 2019


Dear IP-Health readers,

Following the decision by a group of parents of children with cystic fibrosis to found a buyers club to provide access to lower priced generic ivacaftor-lumacaftor (Vertex brand name Orkambi) the UK government yesterday announced that it will look seriously into the option to make Crown use. See for details our lates blog:

https://medicineslawandpolicy.org/2019/06/cystic-fibrosis-buyers-club-shows-the-uk-government-the-way/

Here is an excerpt of the parliamentary meeting where Under Secretary of State for Public Health and Primary care, Seema Kennedy, told parliament yesterday, that in light of ongoing failure of Vertex to offer a fair price the government has a “moral obligation” to explore all options including Crown use and a large scale clinical trial to get access to a generic.
https://parliamentlive.tv/event/index/733e2c79-696a-4261-abc1-73137a2b25a3?in=18:52:20&out=18:53:09

Kind regards,

Ellen ‘t Hoen

————————————————————
Ellen ‘t Hoen LLM, PhD | Medicines Law & Policy
www.medicineslawandpolicy.org
E-mail: ellenthoen at medicineslawandpolicy.net
Twitter: @ellenthoen



More information about the Ip-health mailing list